Involvement of endogenous leukotriene B4 and platelet-activating factor in polymorphonuclear leucocyte recruitment to dermal inflammatory sites in rats

Immunology

Volumn 124, Issue 3, 2008, Pages 295-303

  Bélanger, Caroline ^a   Elimam, Hanan ^a   Lefebvre, Julie ^b   Borgeat, Pierre ^b   Marleau, Sylvie ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b LAVAL UNIVERSITY   (Canada)

Author keywords

Extravasation; Leukotriene B4; Lipid mediator; Lung; Migration; Platelet activating factor; Skin; Trafficking

Indexed keywords

1 [3 (4 BIPHENYLYLMETHYL) 4 HYDROXYCHROMAN 7 YL]CYCLOPENTANECARBOXYLIC ACID; ARACHIDONIC ACID; COMPLEMENT COMPONENT C5A; EDETIC ACID; FOROPAFANT; LEUKOTRIENE B4; LEUKOTRIENE B4 RECEPTOR ANTAGONIST; MYELOPEROXIDASE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SEPHADEX; THROMBOCYTE ACTIVATING FACTOR; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; AUTOCRINE EFFECT; BLOOD SAMPLING; CELLULAR DISTRIBUTION; DRUG INHIBITION; EXTRAVASATION; LEUKOCYTE AGGREGATION; MALE; NEUTROPHIL CHEMOTAXIS; NEUTROPHILIA; NONHUMAN; PARACRINE SIGNALING; PNEUMONIA; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING; SKIN INFLAMMATION;

ANIMALS; BENZOPYRANS; CARBOXYLIC ACIDS; DERMATITIS; DIHYDROPYRIDINES; IMIDAZOLES; LEUKOTRIENE B4; MALE; NEUTROPHIL INFILTRATION; NEUTROPHILS; PLATELET ACTIVATING FACTOR; PLATELET MEMBRANE GLYCOPROTEINS; PNEUMONIA; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, LEUKOTRIENE B4; SKIN; THIAZOLES;

EID: 44849091232     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2007.02767.x     Document Type: Article

References (67)

1. Stafforini DM, McIntyre TM, Zimmerman GA, Prescott SM. Platelet-activating factor, a pleiotrophic mediator of physiological and pathological processes. Crit Rev Clin Lab Sci 2003 40: 643 72.
2. Serhan CN, Savill J. Resolution of inflammation: the beginning programs the end. Nat Immunol 2005 6: 1191 7.
3. Peters-Golden M, Canetti C, Mancuso P, Coffey MJ. Leukotrienes: underappreciated mediators of innate immune responses. J Immunol 2005 174: 589 94.
4. Borgeat P. Biochemistry of the lipoxygenase pathways in neutrophils. Can J Physiol Pharmacol 1989 67: 936 42.
5. Fabre JE, Goulet JL, Riche E, Nguyen M, Coggins K, Offenbacher S, Koller BH. Transcellular biosynthesis contributes to the production of leukotrienes during inflammatory responses in vivo. J Clin Invest 2002 109: 1373 80.
6. Jouvin-Marche E, Ninio E, Beaurain G, Tence M, Niaudet P, Benveniste J. Biosynthesis of Paf-acether (platelet-activating factor). VII. Precursors of Paf-acether and acetyl-transferase activity in human leukocytes. J Immunol 1984 133: 892 8.
7. Garcia MC, Fernandez-Gallardo S, Gijon MA, Garcia C, Nieto ML, Sanchez CM. Biosynthesis of platelet-activating factor (PAF) in human polymorphonuclear leucocytes. The role of lyso-PAF disposal and free arachidonic acid. Biochem J 1990 268: 91 8.
8. Whatley RE, Fennell DF, Kurrus JA, Zimmerman GA, McIntyre TM, Prescott SM. Synthesis of platelet-activating factor by endothelial cells. The role of G proteins. J Biol Chem 1990 265: 15550 9.
9. Prescott SM, Zimmerman GA, McIntyre TM. Human endothelial cells in culture produce platelet-activating factor (1-alkyl-2-acetyl-sn-glycero-3- phosphocholine) when stimulated with thrombin. Proc Natl Acad Sci USA 1984 81: 3534 8.
10. 4 and platelet-activating factor in human neutrophils. Br J Pharmacol 1994 111: 852 60.
11. Sisson JH, Prescott SM, McIntyre TM, Zimmerman GA. Production of platelet-activating factor by stimulated human polymorphonuclear leukocytes. Correlation of synthesis with release, functional events, and leukotriene B4 metabolism. J Immunol 1987 138: 3918 26.
12. Tomhave ED, Richardson RM, Didsbury JR, Menard L, Snyderman R, Ali H. Cross-desensitization of receptors for peptide chemoattractants. Characterization of a new form of leukocyte regulation. J Immunol 1994 153: 3267 75.
13. Marleau S, Fruteau de Laclos B, Sanchez AB, Poubelle PE, Borgeat P. Role of 5-lipoxygenase products in the local accumulation of neutrophils in dermal inflammation in the rabbit. J Immunol 1999 163: 3349 458.
14. Canetti C, Silva JS, Ferreira SH, Cunha FQ. Tumour necrosis factor-alpha and leukotriene B(4) mediate the neutrophil migration in immune inflammation. Br J Pharmacol 2001 134: 1619 28.
15. Gaudreault E, Stankova J, Rola-Pleszczynski M. Involvement of leukotriene B4 receptor 1 signaling in platelet-activating factor-mediated neutrophil degranulation and chemotaxis. Prostaglandins Other Lipid Mediat 2005 75: 25 34.
16. Haribabu B, Verghese MW, Steeber DA, Sellars DD, Bock CB, Snyderman R. Targeted disruption of the leukotriene B(4) receptor in mice reveals its role in inflammation and platelet-activating factor-induced anaphylaxis. J Exp Med 2000 192: 433 8.
17. Shindo K, Koide K, Fukumura M. Enhancement of leukotriene B4 release in stimulated asthmatic neutrophils by platelet activating factor. Thorax 1997 52: 1024 9.
18. Chen M, Lam BK, Kanaoka Y, Nigrovic PA, Audoly LP, Austen KF, Lee DM. Neutrophil-derived leukotriene B4 is required for inflammatory arthritis. J Exp Med 2006 203: 837 42.
19. Kim ND, Chou RC, Seung E, Tager AM, Luster AD. A unique requirement for the leukotriene B4 receptor BLT1 for neutrophil recruitment in inflammatory arthritis. J Exp Med 2006 203: 829 35.
20. Fretland D, Sanderson T, Smith P, Adams L, Carson R, Fuhr J, Tanner J, Clapp N. Oral efficacy of a leukotriene B4 receptor antagonist in colitic cotton-top tamarins. Gut 1995 37: 702 7.
21. Rios-Santos F, Benjamim CF, Zavery D, Ferreira SH, Cunha FQ. A critical role of leukotriene B4 in neutrophil migration to infectious focus in cecal ligation and puncture sepsis. Shock 2003 19: 61 5.
22. Medoff BD, Tager AM, Jackobek R, Means TK, Wang L, Luster AD. Antibody-antigen interaction in the airway drives early granulocyte recruitment through BLT1. Am J Physiol Lung Cell Mol Physiol 2006 290: L170 8.
23. Souza DG, Pinho V, Cassali GD, Poole S, Teixeira MM. Effect of a BLT receptor antagonist in a model of severe ischemia and reperfusion injury in the rat. Eur J Pharmacol 2002 440: 61 9.
24. Souza DG, Coutinho SF, Silveira MR, Cara DC, Teixeira MM. Effects of a BLT receptor antagonist on local and remote reperfusion injuries after transient ischemia of the superior mesenteric artery in rats. Eur J Pharmacol 2000 403: 121 8.
25. 4 receptor antagonist, SC-53228. Inflammation 1995 19: 333 46.
26. Fernandes ES, Passos GF, Campos MM, de Souza GE, Fittipaldi JF, Pesquero JL, Teixeira MM, Calixto JB. Cytokines and neutrophils as important mediators of platelet-activating factor-induced kinin B1 receptor expression. Br J Pharmacol 2005 146: 209 16.
27. Han XB, Liu X, Hsueh W, De Plaen IG. Macrophage inflammatory protein-2 mediates the bowel injury induced by platelet-activating factor. Am J Physiol Gastrointest Liver Physiol 2004 287: G1220 6.
28. Souza DG, Cara DC, Cassali GD, Coutinho SF, Silveira MR, Andrade SP, Poole SP, Teixeira MM. Effects of the PAF receptor antagonist UK74505 on local and remote reperfusion injuries following ischaemia of the superior mesenteric artery in the rat. Br J Pharmacol 2000 131: 1800 8.
29. Qayumi AK, English JC, Godin DV, Ansley DM, Loucks EB, Lee JU, Kim CW. The role of platelet-activating factor in regional myocardial ischemia-reperfusion injury. Ann Thorac Surg 1998 65: 1690 7.
30. Sandoval D, Gukovskaya A, Reavey P, Gukovsky S, Sisk A, Braquet P, Pandol SJ, Poucell-Hatton S. The role of neutrophils and platelet-activating factor in mediating experimental pancreatitis. Gastroenterology 1996 111: 1081 91.
31. Kagoshima M, Tomomatsu N, Iwahisa Y, Yamaguchi S, Matsuura M, Kawakami Y, Terasawa M. Suppressive effects of Y-24180, a receptor antagonist to platelet activating factor (PAF), on antigen-induced asthmatic responses in guinea pigs. Inflamm Res 1997 46: 147 53.
32. Bussolati B, Biancone L, Cassoni P, Russo S, Rola-Pleszczynski M, Montrucchio G, Camussi G. PAF produced by human breast cancer cells promotes migration and proliferation of tumor cells and neo-angiogenesis. Am J Pathol 2000 157: 1713 25.
33. Meenan J, Grool TA, Hommes DW et al. Lexipafant (BB-882), a platelet activating factor receptor antagonist, ameliorates mucosal inflammation in an animal model of colitis. Eur J Gastroenterol Hepatol 1996 8: 569 73.
34. Mathiak G, Szewczyk D, Abdullah F, Ovadia P, Rabinovici R. Platelet-activating factor (PAF) in experimental and clinical sepsis. Shock 1997 7: 391 404.
35. Tremblay P-B, Macari DMT, Martel D, du Souich P, Barja-Fidalgo C, Marleau S. Hypoxemia modifies circulating and exudate neutrophil numbers and functional responses in carrageenin-induced pleurisy in the rat. J Leukoc Biol 2000 67: 785 92.
36. 4 plays a critical role in the progression of collagen-induced arthritis. Proc Natl Acad Sci USA 1995 92: 517 21.
37. 4-receptor interaction suppresses eosinophil infiltration and disease pathology in a murine model of experimental allergic encephalomyelitis. J Exp Med 1996 183: 1893 8.
38. Aiello RJ, Bourrassa P-A, Lindsey S, Weng W, Freeman A, Showell HJ. Leukotriene B4 receptor antagonism reduces monocytic foam cells in mice. Arterioscler Thromb Vasc Biol 2002 22: 443 9.
39. 4 receptors delays cardiac allograft rejection in mice. Transplantation 1999 67: 808 15.
40. Prescott SM, McIntyre TM, Zimmerman GA. The role of platelet-activating factor in endothelial cells. Thromb Haemost 1990 64: 99 103.
41. Ogino M, Majima M, Kawamura M, Hatanaka K, Saito M, Harada Y, Katori M. Increased migration of neutrophils to granulocyte colony-stimulating factor in rat carrageenin-induced pleurisy: roles of complement, bradykinin, and inducible cyclooxygenase-2. Inflamm Res 1996 45: 335 46.
42. 4 receptors in vitro. Br J Pharmacol 1996 117: 1127 32.
43. 4 receptor antagonist CP-105696. J Pharmacol Exp Ther 1995 273: 176 84.
44. Turner CR, Breslow R, Conklyn MJ et al. In vitro and in vivo effects of leukotriene B4 antagonism in a primate model of asthma. J Clin Invest 1996 97: 381 7.
45. Liston TE, Conklyn MJ, Houser J, Wilner KD, Johnson A, Apseloff G, Whitacre C, Showell HJ. Pharmacokinetics and pharmacodynamics of the leukotriene B4 receptor antagonist CP-105,696 in man following single oral administration. Br J Clin Pharmacol 1998 45: 115 21.
46. Herbert JM, Bernat A, Valette G et al. Biochemical and pharmacological activities of SR 27417, a highly potent, long-acting platelet-activating factor receptor antagonist. J Pharm Exp Ther 1991 259: 44 51.
47. Herbert JM, Laplace MC, Bernat A, Salel V, Maffrand JP. Effect of SR 27417 on oedema formation induced in rabbit skin by platelet-activating factor or antigen. Eur J Pharmacol 1992 216: 175 81.
48. Bernat A, Herbert JM, Salel V, Lespy L, Maffrand JP. Protective effect of SR 27417, a novel PAF antagonist, on PAF- or endotoxin-induced hypotension in the rat and the guinea-pig. Journal Lipid Mediators 1992 5: 41 8.
49. Herbert JM, Lespy L, Maffrand JP. Protective effect of SR 27417, a novel PAF antagonist, on lethal anaphylactic and endotoxin-induced shock in mice. Eur J Pharmacol 1991 205: 271 6.
50. Herbert JM, Bernat A, Tibiriça E. Effect of SR 27417, a novel PAF antagonist on antigen-induced hypotension in the rat. J Lipid Mediators Cell Signalling 1996 15: 115 23.
51. 4 by human neutrophils in response to platelet-activating factor. Enhancement of both arachidonic acid availability and 5-lipoxygenase activation. J Immunol 1991 146: 1204 11.
52. Wijkander J, O'Flaherty JT, Nixon AB, Wykle RL. 5-Lipoxygenase products modulate the activity of the 85-kDa phospholipase A2 in human neutrophils. J Biol Chem 1995 270: 26543 9.
53. Rubin BB, Downey GP, Koh A et al. Cytosolic phospholipase A2-alpha is necessary for platelet-activating factor biosynthesis, efficient neutrophil-mediated bacterial killing, and the innate immune response to pulmonary infection: cPLA2-alpha does not regulate neutrophil NADPH oxidase activity. J Biol Chem 2005 280: 7519 29.
54. Yamaki K, Oh-Ishi S. Release of leukotriene B4 and 6-keto-prostaglandin F1 alpha from rat leukocytes in response to platelet-activating factor or Ca-ionophore A23187. J Lipid Mediat 1990 2: 317 27.
55. Komatsu H, Amano M. Inhibition of leukotriene B4-induced increase in intracellular calcium ion level of human peripheral blood polymorphonuclear leukocytes by Y-24180, an antagonist of platelet-activating factor receptor. Int J Immunopharmacol 1997 19: 661 7.
56. Hotter G, Closa D, Prats N, Pi F, Gelpi E, Rosello-Catafau J. Free radical enhancement promotes leucocyte recruitment through a PAF and LTB4 dependent mechanism. Free Radic Biol Med 1997 22: 947 54.
57. Jancar S, Braquet P, Sirois P. Interactions of arachidonic acid metabolites and platelet activating factor and mechanism of action in hypersensitivity reactions. Braz J Med Biol Res 1987 20: 487 94.
58. Jancar S, Braquet P, Sirois P. Release of eicosanoids in rat peritoneal cavity during the Arthus reaction. Effect of the PAF-antagonist BN-52021 and indomethacin. Int J Immunopharmacol 1989 11: 129 32.
59. Dallob A, Guindon Y, Goldenberg MM. Pharmacological evidence for a role of lipoxygenase products in platelet-activating factor (PAF) -induced hyperalgesia. Biochem Pharmacol 1987 36: 3201 4.
60. Moodley I, Stuttle A. Evidence for a dual pathway in platelet activating factor-induced aggregation of rat polymorphonuclear leucocytes. Prostaglandins 1987 33: 253 64.
61. Palmantier R, Surette ME, Sanchez A, Braquet P, Borgeat P. Priming for the synthesis of 5-lipoxygenase products in human blood ex vivo by human granulocyte-macrophage colony-stimulating factor and tumor necrosis factor-alpha. Lab Invest 1994 70: 696 704.
62. Clancy RM, Dahinden CA, Hugli TE. Arachidonate metabolism by human polymorphonuclear leukocytes stimulated by N-formyl-Met-Leu-Phe or complement component C5a is independent of phospholipase activation. Proc Natl Acad Sci USA 1983 80: 7200 4.
63. Bauldry SA, Wooten RE. Leukotriene B4 and platelet activating factor production in permeabilized human neutrophils: role of cytosolic PLA2 in LTB4 and PAF generation. Biochim Biophys Acta 1996 1303: 63 73.
64. Stack WA, Jenkins D, Vivet P, Hawkey CJ. Lack of effectiveness of the platelet-activating factor antagonist SR27417A in patients with active ulcerative colitis: a randomized controlled trial. The Platelet Activating Factor Antagonist Study Group in Ulcerative Colitis. Gastroenterology 1998 115: 1340 5.
65. Diaz-Gonzalez F, Alten RH, Bensen WG et al. Clinical trial of a leukotriene B4 receptor antagonist, BIIL 284, in patients with rheumatoid arthritis. Ann Rheum Dis 2007 66: 628 32.
66. Maghni K, Blanchette F, Sirois P. Induction of lung eosinophilia and neutrophilia in guinea pigs following injection of sephadex beads. Inflammation 1993 17: 537 50.
67. Oliveira SH, Costa CH, Ferreira SH, Cunha FQ. Sephadex induces eosinophil migration to the rat and mouse peritoneal cavity: involvement of mast cells, LTB4, TNF-alpha, IL-8 and PAF. Inflamm Res 2002 51: 144 53.